Cyclin D dysregulation and overexpression is noted in the majority of multiple myeloma (MM) patients, suggesting its critical role in MM pathogenesis. Here, we sought to identify the effects of targeting cyclin D in MM. We first confirmed cyclin D mRNA overexpression in 42 of 64 (65%) patient plasma cells. Silencing cyclin D1 resulted in 450% apoptotic cell death suggesting its validity as a potential therapeutic target. We next evaluated P276-00, a clinical-grade small-molecule cyclindependent kinase inhibitor as a way to target the cyclins. P276-00 resulted in dose-dependent cytotoxicity in MM cells. Cell-cycle analysis confirmed either growth arrest or caspasedependent apoptosis; this was preceded by inhibition of Rb-1 phosphorylation with associated downregulation of a range of cyclins suggesting a regulatory role of P276-00 in cell-cycle progression through broad activity. Proliferative stimuli such as interleukin-6, insulin-like growth factor-1 and bone-marrow stromal cell adherence induced cyclins; P276-00 overcame these growth, survival and drug resistance signals. Because the cyclins are substrates of proteasome degradation, combination studies with bortezomib resulted in synergism. Finally, in vivo efficacy of P276-00 was confirmed in an MM xenograft model. These studies form the basis of an ongoing phase I study in the treatment of relapsed/refractory MM.
Introduction
Multiple myeloma (MM) is a hematological malignancy characterized by a clonal proliferation and infiltration of the bone marrow (BM) by plasma cells (PCs). 1, 2 In 2008, an estimated 19 920 new cases of MM will be diagnosed in the United States and 10 790 deaths will be attributed to this disease 3 accounting for a disproportionate 2% cancer-related death rate. Despite currently available treatments including thalidomide, 4 ,5 bortezomib, 6,7 lenalidomide 8 and autologous transplantation 9 resulting in an improvement in overall survival of our patients, 10 MM remains incurable underscoring the need for a continued search for novel therapeutics.
One major limitation to the development of anti-MM therapy is its heterogeneity. Recent studies of our understanding of the molecular pathogenesis of MM have resulted in a new proposed classification of MM subdividing patients into groups based on supervised gene expression profiles. [11] [12] [13] Chromosomal abnormalities associated with MM are broadly classified into hyperdiploid, accounting for 50% of the tumors, and nonhyperdiploid (NHRD), including tumors hypodiploid, pseudodiploid or subtetraploid. These NHRD tumors have been associated with a poorer prognosis. Five recurrent IgH translocations have been seen in MM including MMSET and FGFR3 (15%), cyclin D3 (3%), cyclin D1 (15%), c-maf (5%) and MAFB (2%) accounting for a prevalence of 40%. Recent evidence suggests that three of these five translocations are predominant in the NHRD tumors. 11, 14, 15 All MM tumor cells have high levels of cyclin D1, D2 and/or D3, including monoclonal gammopathy of unknown significance, suggesting an early unifying oncogenic event. [11] [12] [13] 16, 17 Dysregulation of the cyclin genes may be a result of known immunoglobulin G translocations, or by presently unknown mechanisms. For example, mechanisms of cyclin D dysregulation include IgH translocations that can directly affect cyclins D1 or D3, MAF or MAFB transcription factors that target cyclin D2 and biallelic dysregulation of the cyclin D1 gene. Cyclin D1 is specifically dysregulated by translocation (11q13) or biallelic dysregulation in over 50% of MM tumors. These molecular insights have allowed for a classification based on the five major translocations and cyclin D overexpression in MM. Thus, cyclin D overexpression in nearly all MM patients is a critical common hallmark in this otherwise heterogeneous disease and may be involved in the progression of MM (Table 1) .
Given the crucial role played by the cyclins in MM, and specifically cyclin D1, in 50% of MM, we asked in the present study: (1) whether targeting cyclin D1 in MM was of potential therapeutic benefit; (2) whether P276-00, 18 ,19 a known smallmolecule cyclin-dependent kinase (Cdk) inhibitor with activity against Cdk4/cyclin D1 had preclinical activity in MM and (3) whether combining P276 with other novel and conventional agents would provide improved efficacy in MM.
Materials and methods

Cell culture and reagents
Dexamethasone (Dex)-sensitive (MM.1S) and Dex-resistant (MM.1R) human MM cell lines were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). Doxorubicin-resistant (Dox40) and melphalan-resistant (LR5) RPMI-8226 human MM cells were kindly provided by Dr William Dalton (Moffitt Cancer Center, Tampa, FL, USA). OPM2 cell line was obtained from Dr Lief Bergsagel (Mayo Clinic, Scottsdale, AZ, USA) and U266 cell line was obtained from ATCC (Rockville, MD, USA). All MM cell lines were cultured in RPMI-1640 media (Sigma Chemical, St Louis, MO, USA) containing 10% fetal bovine serum (FBS), 2 mmol/l L-glutamine (Gibco, Grand Island, NY, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). INA-6 cells were grown in RPMI-1640 medium containing interleukin-6 (IL-6, 10 ng/ml). BM aspirates of patients with MM were obtained after informed consent and approval by the institutional review board. The samples were processed by Ficoll-Paque gradient, and mononuclear cells (MNCs) were separated. MM cells were separated by negative selection as previously described. 20 For the generation of bone-marrow stromal cells (BMSCs), MNCs were placed in 25 mm 2 culture flasks in RPMI-1640 media (Sigma Chemical) containing 20% FBS, 2 mmol/l L-glutamine (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). Once confluent, the cells were trypsinized and passaged as needed. For the experiments, BMSCs were incubated in 96-well culture plates (approximately 5000-10 000 BMSCs per well) for 24 h or grown to confluence in 6-well plates. The media were washed off and MM cells were added to the wells (2 Â 10 4 cells per well) and incubated with media or with increasing concentrations of P276-00 for the specified times at 37 1C. Peripheral blood mononuclear cells (PBMCs) were derived from healthy donors and similarly tested.
P276-00
P276-00 was obtained from Nicholas Piramal Ltd, Mumbai, India. 18, 19 The drug was dissolved in dimethyl sulfoxide (DMSO; Sigma Chemical, St Louis, MO, USA) at a concentration of 200 mmol/l (200 mM) and stored at À20 1C until use; it was diluted in culture medium (1-4000 nM, o0.1% DMSO in the final concentration) immediately before use and was used within 4 h.
Gene expression profiling
The gene expression data for results shown in Figure 1a were obtained from the National Center for Biotechnology Information Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO series accession no. GSE4452. 21 shRNA sequences and plasmid constructs
The cyclin D1 MISSION shRNA Plasmid DNA was used (Sigma-Aldrich Corporation, St Louis, MO, USA). The target sequence of cyclin D1 was as follows: CCGGGCCAGGATGA TAAGTTCCTTTCTCGAGAAAGGAACTTATCATCCTGGCTTTT TG. An shGFP Plasmid DNA (unrelated to cyclin D1) was used as a negative control. MISSION TurboGFP Control Vector was used for measuring transfection efficiency by visual confirmation of successful transfection. The plasmids were cloned by transformation in competent DH5-alpha Escherichia coli bacteria cells, following manufacturer's protocol and a DNA Miniprep Kit was used to purify the DNA.
Cell culture, transfection and lentiviral infection
HEK293T cells were cultured under standard conditions ( Adapted from Bergsagel et al.
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Preclinical activity of P276-00 in myeloma N Raje et al modified Eagle's medium supplemented with 10% FBS. MM cells (MM1S and INA-6) cells were grown in RPMI-1640 medium as previously described. IL-6 (10 ng/ml) was added to INA-6 MM cells. Self-inactivating lentiviral particles were produced by cotransfecting into 293T cells the packaging plasmids pCMVD8.2 (GAG-POL DNA), the vesicular stomatitis virus-G envelope plasmid pMD.G, concomitant with the lentiviral expression construct of interest: shRNA cyclin D1 or shGFP as negative control vector; or TurboGFP Control Vector plasmid mixed with lipofectamine reagent and OPTI-MEM serum free media.
At 24, 48 and 72 h post-transfection, supernatants containing pseudoviral particles were collected; aliquots with 8 mg/ml polybrene were added to exponentially growing MM1S and INA-6 cells (1 Â 10 5 per ml). Cells were washed in phosphatebuffered saline (PBS) 24 h after transduction and fresh medium was supplemented at 24 h after infection. The infectivity was determined (after 72 h) by fluorescence-activated cell sorting analysis of green fluorescent protein-positive (GFP þ ) cells. Cyclin D1 was overexpressed by adenoviral transduction of MM1.S MM cell line. The recombinant replication-defective adenovirus ADV-D1, a kind gift from Dr JH Albrecht (University of Rochester, NY, USA), was prepared as previously described. 22 Recombinant ADV-D1 adenovirus was then isolated by plaque purification, and a single clone was used for largescale amplification for use in later experiments. The identity of this clone was confirmed by Southern blot analysis demonstrating the presence of cyclin D1 cDNA. Viral titers were determined by a plaque-forming unit assay. Viral stock was stored at À80 1C. ADV-bgal, which is an identical construct containing the nuclear localizing variant of b-galactosidase, was also provided by Dr Albrecht, and large-scale amplification and titration of this virus was performed in an identical manner.
MM1.S MM cells were transduced by addition of ADV-D1 or ADV-bgal in medium at a dose of 20-200 plaque-forming units per cell. After 4 h, the media containing adenovirus were washed out and then replaced with virus-free medium. Transduction efficiency was determined by b-galactosidase assay (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's manual. Cells were used for experiments after transduction as outlined.
Cell viability and proliferation assays
Colorimetric assays were performed to assay drug activity at increasing concentrations of P276-00. Cells from 24-or 48-h cultures were pulsed with 10 ml of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International Inc., Temecula, CA, USA) to each well; the 96-well plates were incubated at 37 1C for 4 h, followed by 100 ml isopropanol containing 0.04 N HCl. Absorbance was read at a wavelength of 570 nm (with correction using readings at 630 nm) on a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA, USA).
Studies with combinations of bortezomib (1-5 nM) were similarly performed in 24 h cultures, and cytotoxicity was determined by MTT.
DNA synthesis was measured by tritiated thymidine uptake ( 3 H-TdR; PerkinElmer, Boston, MA, USA) as previously described. 23, 24 Briefly, MM cells (2-3 Â 10 4 cells per well) were incubated in 96-well culture plates (Costar, Cambridge, MA, USA) in the presence of media or varying concentrations of P276-00 for 24 h at 37 1C. For evaluation of the effect of growth factors, recombinant IL-6 (10 ng/ml) or insulin-like growth factor 1 (IGF-1, 50 ng/ml) was added to the wells at the beginning of the incubation to obtain the final concentration indicated. Cells were pulsed with 3 H-TdR (0.5 mCi per well) during the last 8 h of 24-h cultures, harvested onto glass filters with an automatic cell harvester (Cambridge Technology, Cambridge, MA, USA) and counted by using the LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD, USA). All experiments were performed in triplicate.
Cell-cycle analysis and detection of apoptosis MM cells (1 Â 10 6 ) were cultured for the specified times in media alone, or with 800 nM of P276-00. The cells were harvested, washed with ice-cold PBS, fixed with 70% ethanol for 1 h and pretreated with 10 mg/ml of RNAse (Sigma Chemical) for 1 h. Cells were stained with propidium iodide (PI; 5 mg/ml; Sigma Chemical), and cell-cycle profile was determined by using the RXP Cytomics software on an Epics flow cytometer (Coulter Immunology, Hialeah, FL, USA), as in earlier studies. MM cells were also incubated for 24 h with increasing concentrations of P276-00, and cell-cycle profile was determined.
Western blotting
Multiple myeloma cells were cultured with P276-00 (800 nM) for the specified times, harvested, washed and lysed using lysis buffer (50 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 150 mmol/l NaCl, 1% Triton X-100, 30 mmol/l sodium pyrophosphate, 5 mmol/l EDTA, 2 mmol/l Na 3 VO 4 , 5 mmol/l NaF, 1 mmol/l phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin and 5 mg/ml aprotinin). For detection of apoptosis-related proteins, cell lysates were subjected to SDSpolyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and immunoblotted with antibodies against cleaved poly(ADP-ribose) polymerase (PARP) and cleaved caspase 8 (Cell Signaling Technology, Beverly, MA, USA). The membrane was stripped and reprobed with anti-tubulin Ab (Santa Cruz Biotech, Santa Cruz, CA, USA) to ensure equal protein loading.
To characterize molecular mechanisms of action, immunoblotting was carried out with anti-cyclin A, cyclin B1, cyclin D1, cyclin D2, cyclin D3 and cyclin E, and Cdk4, anti-phospho retinoblastoma (Rb; Ser 807/811), and anti-phospho STAT3 (Cell Signaling Technology) antibodies. Anti-apoptotic proteins including Mcl-1 (Santa Cruz Biotech) and the BCL family proteins were similarly probed. Antigen-antibody complexes were detected by using enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). Blots were stripped and reprobed with anti-tubulin Ab to ensure equal protein loading. Z-VAD FMK (25 mM); Bachem, Bubendorf, Switzerland) was used to pretreat MM cells for 2 h before addition of P276-00 to block caspase activation.
In vivo studies of P276-00
The in vivo anti-MM activity of P276-00 was evaluated in a previously established GFP þ MM xenograft model in severe combined immunodeficient (SCID) mice by serially monitoring with whole-body fluorescence imaging. Briefly, 30 male (6-to 8-week-old) CB17-SCID mice were obtained from Jackson Laboratories (Charles River Laboratories, Wilmington, MA, USA), housed and monitored in the Animal Research Facility of the Dana-Farber Cancer Institute, g-irradiated (2 Gy, 200 rad) using cesium 137 ( 137 Cs) g-irradiator source and injected 24 h after irradiation subcutaneously with 2.5 Â 10 6 MM1.S/S-GFP þ cells suspended in total volume of 100 ml of RPMI-1640 medium per mouse. Treatment with P276 was Preclinical activity of P276-00 in myeloma N Raje et al started initially at 35 mg/kg i.p. thrice weekly (TIW). This was modified after treatment of the first five animals because of a 12% weight loss within their first week, and subsequently all animals were treated at 25 mg/kg i.p. TIW. Treatment was initiated only after palpable subcutaneous tumors, confirmed by the presence of tumor on fluorescence imaging. Mice were monitored daily for changes in body weight, signs of infection and with TIW fluorescence imaging. In accordance with institutional guidelines, mice were humanely killed by CO 2 inhalation in the event of tumor size 43 cm or major compromise in their quality of life. All experimental procedures and protocols had been approved by the Animal Care and Use Committee of the Dana-Farber Cancer Institute. Tumors from animals were subjected to immunohistochemical analysis at the time of death or killing and probed with anti-caspase 3 antibody. Overall survival truncated at 30 days (defined as time between i.p. injection of tumor cells and 30 days or death) was compared in control vs P276-00-treated mice by the KaplanMeier method.
Results
Cyclin D1 is overexpressed in MM cells and targeting cyclin D1 by shRNA results in MM cell apoptosis Previous studies have documented overexpression and activation of the cyclins in MM cells. 12, 15 We therefore first extended these findings by investigating endogenous expression levels of cyclin D1 from a public repository of normal PCs and patient MM tumor gene expression profiles. 21 Cyclin D1 was overexpressed in 42 of 64 MM patients (65%; Figure 1a) . Similarly, cyclin D2 overexpression was also noted in MM cells. To assess the importance of targeting cyclin D1, we next used shRNA lentiviral constructs to silence cyclin D1 in MM1.S and INA-6 MM cells. The specificity of shRNA was evident by decrease in cyclin D1 in both MM.1S and INA-6 cells (Figure 1b) . Importantly, our data demonstrated increased apoptotic/necrotic cell death in cyclin D1 shRNA-vs control-transfected MM cells (MM1.S: 20.9 vs 58.2%; INA-6: 31.2 vs 48.5%) at 9 days after transfection, indicating that small-molecule Cdk inhibitors may provide a valuable therapeutic tool to target cyclin D1 (Figure 1b ).
P276-00 treatment results in decreased viability of MM cells in a dose-dependent manner with associated downregulation of cyclin D
We next examined P276-00, a small-molecule Cdk inhibitor with potent inhibitory activity against Cdk4/cyclin D1. The effect of P276-00 on viability of MM cells was determined by MTT assays. MM cell lines sensitive (MM.1S, OPM2, RPMI, U266, INA-6, KMS 12-BM) and resistant (Dox40, LR5, MM1.R) to conventional therapies were cultured in the presence of increasing doses of P276-00 (0-1500 nmol/l) for 48 h. As demonstrated in Figure 2a , P276-00 treatment resulted in dose-dependent cytotoxicity with IC 50 ranging from 400 to 1000 nmol/l at 48 h without any cytotoxicity of PBMCs (data not shown). This was associated with a decrease in cyclin D1 protein expression in MM.1S, OPM2, U266 and INA-6 MM cell lines. As cyclin D1 is not uniformally expressed in all MM cells we probed for cyclin D2 and D3 in MM cells. Although no significant changes were noted in cyclin D2 protein expression, cyclin D3 was inhibited in the majority of MM cells (Figure 2b) .
To address the specificity of P-276-00, we tested increasing doses of P276-00 in MM cells transfected with cyclin D1. As shown in Figure 2c (left), MM1 .S MM cells with adenoviraltransfected cyclin D1 overexpression were relatively more resistant to P276-00-induced cytotoxicity in 24 h cultures (Figure 2c, right) , suggesting that P276-00-induced MM apoptosis was at least, in part, mediated by inhibition of Cdk4/cyclin D1.
P276-00 treatment results in either caspase-dependent apoptosis or growth arrest of MM cells
To further characterize the cytotoxic effect of P276-00 on MM cells, we performed cell-cycle analysis on MM1.S cells cultured with media alone or P276-00 (800 nmol/l) for the specified time points. As demonstrated in Figure 3a , P276-00 resulted in an increase in sub-G 1 cells with maximal effect noted at 48 h (35% sub-G 1 fraction). This was preceded by an increase in PARP and caspase 3 and 9 cleavage with modest effects on caspase 8 activity, suggesting activation of predominantly intrinsic apoptotic pathway.
To confirm P276-00-induced apoptosis was caspase dependent, we treated cells with ZVAD-FMK (25 mM) for 2 h before treatment with increasing concentrations of P276-00 (24 h). As demonstrated in Figure 3b , P276-00-induced apoptosis was blocked by Z-VAD pretreatment, evidenced by cell-cycle analysis and confirmed by MTT assay.
We also studied the effects of P276-00 on Dox40 and OPM1 MM cells (Figure 3c ) and saw 450% apoptosis of Dox40 vs OPM1 MM cells where G 2 M arrest was noted suggesting that P276-00 effects were cell-line specific.
P276-00 induces dose-and time-dependent downregulation of Cdk4, other cyclins and pRB
Given that P276-00 had effects on other Cdks and cyclins based on in vitro kinase assays, 19 we studied its effects on other cyclins and signaling cascades. MM cells (MM1.S, RPMI-8226, OPM1, OPM2, U266, INA-6, Dox40, LR5) were incubated with P276-00 (800 nM) for 6 h; cell lysates were prepared as previously described. 23, 24 P276-00 treatment resulted in downregulation of cyclin B1 in all cell lines tested (Figure 4a ). This was related to Cdk4 downregulation in some MM cells. This was also associated with a downregulation of pRb (Ser 807/811) in the majority of cell lines (data not shown). Next, MM1.S cells were incubated with P276-00 (800 nM) for 1, 2, 4 and 6 h or for 6 h at increasing drug concentrations (0-1000 nM); P276-00 downregulated cyclin B1 and Cdk4 expression in a time-and dosedependent manner, with only modest effects on cyclin E (Figure 4b ). pRB (Ser 780) was also downregulated at very early time points, along with downregulation of Cdk4 and the cyclins.
Effect of P276-00 on cell signaling was tested in MM1.S MM cells. P276-00 treatment resulted in a dose-and time-dependent inhibition of pSTAT3 (Figure 4c ). This was accompanied by a time-and dose-dependent inhibition of pP65. Conversely, pERK was upregulated in MM cells.
P276-00 overcomes the protective effects conferred by cytokines (IL-6 and IGF-1) and BMSCs, and is active in patient-derived MM cells
We next examined the effects of P276-00 on MM cells cultured in the presence of IL-6 (10 ng/ml) and IGF-1 (25 ng/ml) ( Figure 5a ). As shown in Figure 5b , P276-00 inhibited DNA synthesis in a dose-dependent manner in MM cells at 48 h in the presence of BMSCs, accompanied by inhibition of cyclin D1 and pRB. To confirm the activity of P276-00 in patient MM cells, we isolated CD138 þ tumor cells from six MM patients with
Preclinical activity of P276-00 in myeloma N Raje et al relapsed disease. P276-00 treatment resulted in dose-and timedependent cytotoxicity of patient-derived MM cells (Figure 5c , left), with downregulation of cyclin B1 in patients 1 and 2, whereas cyclin D1 was downregulated in patient 1 (Figure 5c , right) following 6 h incubation of patient CD138 þ cells with 800 nM of P276-00. No cyclin D1 expression was noted in patient 2.
P276-00 has synergistic anti-MM activity when combined with bortezomib
Given that the cyclins are substrates of the proteasome, 25 we next examined MM cell cytotoxicity of P276-00 in combination with bortezomib. Increasing concentrations of P276-00 (0-1000 nM) were added with bortezomib (0-5 nM), and MM cell cytotoxicity was assayed by MTT at 24 h (Figure 5d ). Synergism was confirmed by applying the Chou-Talalay method to calculate a combination index (CI), as previously described. 23, 26 As shown in Figure 5d (left), strong synergism was noted at a wide range of concentrations tested, evidenced by CI of o1. Combination treatment resulted in downregulation of pRb, Cdk4 and cyclin D1 following 6 h of treatment when compared to bortezomib-treated cells alone (Figure 5d, right) where the cyclins were increased given that they are substrates of the proteasome.
P276-00 is active in an MM xenograft model
To confirm the in vivo activity of P276-00, we next treated 30 CB17-SCID mice bearing subcutaneous GFP þ MM1.S plasmacytomas with either saline (n ¼ 9) or P276-00 (n ¼ 21). We Preclinical activity of P276-00 in myeloma N Raje et al initially used 35 mg/kg TIW, which was changed to 25 mg due to a 12% weight loss after treatment of the first five animals. Tumor volume was decreased in treated animals (793 ± 100 mg) vs controls (4144±200 mg) at 30 days (Figure 6a, left) . This was further confirmed by decreased bioluminescence in treated animals (21 333 vs 4737; Figure 6b ). Mice treated with P276-00 had a 10% weight loss while on the study drug. Following killing or death tumors were subjected to immunohistochemistry and probed with anti-caspase 3 antibody. A representative example is shown in Figure 6a (right) . Because all mice were killed once tumor size increased maximally at 3 cm in diameter, survival as demonstrated by a Kaplan-Meier curve using a logrank analysis was truncated at 30 days. A significant survival benefit was observed in treated vs control animals (P ¼ 0.05), as shown in Figure 6c . Preclinical activity of P276-00 in myeloma N Raje et al phosphorylation of the Rb gene product, resulting in the release of the E2F transcription factors and activation of E2F-responsive genes, promoting entry of cells into S phase. Cdk4 and 6 complex with the various D cyclins and regulate G 1 -S phase transition. Because uncontrolled proliferation of cancer cells is a consequence of dysregulation of Cdks and/or their cyclin complexes as well as their inhibitors, Cdk inhibitor therapies have been developed and are currently being studied in various tumor types. 27, 30, 31 Given the critical function of the D-type cyclins in MM and specifically cyclin D1, we here determined whether targeting cyclin D1 had therapeutic potential in MM. We first confirmed the overexpression of cyclin D1 in patient-derived MM cells by gene expression studies. Although cyclin D1 is overexpressed in MM cells, its relevance remains to be determined. Krieger et al. 32 showed that cyclin D1a and b mRNA isoforms were both expressed in MM. However, the protein form of cyclin D1b was rarely expressed. Moreover, given its short half-life and lack of localization to the nucleus, it is unlikely to have transforming capacity. Dysregulation of cyclin D1 by t (11;14) translocation is seen in a small percentage of MM patients. The remaining patients show a biallelic expression, accounting for either dysregulation or overexpression in more than 50% of MM patients. Mice lacking the individual D cyclins and Cdk4 and 6 have been generated with tissue-specific differences between mice. 33 More recently, mice lacking all D cyclins have also been generated, 34 which showed specific defects in the hematopoietic system and died at embryonal day 17.5. Mice lacking Cdk4/6 had a very comparable phenotype, and died early during embryonal development with multi-lineage hematopoietic abnormalities. 35 These data suggest that different cell types may function in a cyclin-dependent and -independent manner. In the context of MM, cyclin D1 has to date not shown any transforming capacity. However, cyclin D overexpression may render MM cells more responsive to proliferative stimuli and therefore contribute to growth, survival and drug resistance. Thus, although the exact role of cyclin D1 dysregulation in MM remains to be determined, it represents an attractive therapeutic target. Our studies using a lentiviral system to knockdown cyclin D1 in MM cells resulting in increased apoptosis of MM cells confirm its therapeutic potential.
Subsequently, we have tested P276-00, a clinical-grade smallmolecule Cdk inhibitor in the context of MM. P276-00 was synthesized following a Cdk4-D1 enzyme assay screen. It is a flavone derivative and inhibits the interaction of cyclin D1 with Cdk4, and cyclin B with Cdk1, and is more specific than other Cdk inhibitors studied to date. 18, 19 In vitro kinase assays for P276-00 exhibited potent inhibitory activity against Cdk4-D1, Cdk1-B and Cdk9-T1 at low nanomolar concentrations. Enzyme kinetics have demonstrated that P276-00 is a competitive inhibitor of the Cdk4-D1 enzyme complex, competing with ATP for the ATP-binding site on the enzyme. Its activity has been demonstrated in several xenograft models including lung and colon. Because of its relative specificity for Cdk4-cyclin D1 complex and its development as a clinical-grade compound, we tested this in MM. Our data demonstrate that P276-00 resulted in apoptosis or growth arrest of MM cells only in part due to its actions on Cdk4/D1. In addition, P276-00 also resulted in Figure 5 P276-00 overcomes the protective effects conferred by interleukin-6 (IL-6), insulin-like growth factor 1 (IGF-1) and bone-marrow stromal cells (BMSCs) on multiple myeloma (MM) cells, is active in patient MM cells and is synergistic with bortezomib. MM1.S cells were cultured for 24 h in the presence of IL-6 (10 ng/ml), IGF-1 (50 ng/ml) and BMSCs in absence and presence of increasing doses of P276-00. P276-00 induced dose-dependent inhibition of DNA synthesis of MM cells at 24 h in the presence of cytokines and BMSCs (a, b) associated with downregulation of cyclin D1 and associated retinoblastoma (Rb) phosphorylation. CD138 þ patient-derived MM cells were tested in cytotoxicity assays at 24 and 48 h and by western blot at 6 h. P276-00 resulted in a dose-and time-dependent toxicity, associated with downregulation of cyclin B1 and D1 expression at 6 h (c). Increasing concentrations of P276-00 were added with bortezomib (0-5 nM) and MM.1S cytotoxicity was assayed by MTT. Synergism was confirmed by calculating a combination index (CI) o1 over a wide range of dosages associated with a downregulation of cyclin D1, Cdk4 and pRB (d), which were increased with bortezomib treatment alone.
Preclinical activity of P276-00 in myeloma N Raje et al downregulation of other cyclins including cyclin B1 as suggested by in vitro kinase assays 19 and cyclin D3 P276-00 was also noted to have activity in nanomolar concentrations against Cdk9-cyclin T, which forms a complex with positive transcription factor B to serve as a transcriptional repressor. 36 Therefore, it is also likely that the apoptosis noted in MM cells results from effects of P276-00 on Cdk9-cyclin T complex, resulting in transcriptional inhibition.
Because the cyclins render MM cells more susceptible to growth and proliferative stimuli and may mediate drug resistance, 2 we have also studied the effects of P276-00 on MM cells in the presence of cytokines, such as IL-6 and IGF-1, and BMSCs. Our data demonstrate that P276-00 overcomes the growth and survival advantage conferred by cytokines and BMSCs suggesting that it can overcome drug resistance. Given that the cyclins and Cdks are substrates of the proteasome, 25 and that proteasome inhibition may result in accumulation of these proteins conferring drug resistance, we combined bortezomib with P276-00. Our data demonstrate marked synergism of P276-00 with bortezomib. Another potential mechanism for this synergism may also be activation of alternate apoptotic signaling cascades where P276-00 predominantly activates the intrinsic pathway, whereas bortezomib acts predominantly on caspase 8. Most Cdk and cell-cycle inhibitors in clinical use are nonspecific and highly cytotoxic. 27 Flavopiridol, like P276-00, is a flavone derivative that has been clinically tested. Unlike P276-00, flavopiridol inhibits all Cdks as well as other kinases, and binds to DNA. Other Cdk inhibitors, such as UCN-01 and seliciclib, are also not specific and affect a broad range of kinases. More recently, specific inhibition of Cdk4/6 by PD 0332991, an orally bioavailable small-molecule Cdk inhibitor Preclinical activity of P276-00 in myeloma N Raje et al has demonstrated growth arrest in MM cells. 37 PD 0332991 in combination with steroids triggered MM cell apoptosis suggesting its utility with conventional and novel agents. Here we show that P276-00 induces apoptosis in the majority of MM cells. In keeping with the in vitro kinase assays, most of its effects appear related to Cdk4/cyclin D1 and Cdk1/cyclin B inhibition. It is undergoing phase I clinical trial evaluation in patients with solid tumors and to date has demonstrated a favorable toxicity profile, further supporting its clinical evaluation in MM as well. Here, we demonstrate its in vitro activity, which is at least, in part, related to cyclin D1/Cdk4 inhibition. Importantly, we have demonstrated apoptosis of MM cells and P276-00 was able to overcome growth and proliferative signals that mediate drug resistance. We have also demonstrated preclinical activity of P276-00 in our xenograft MM model. In aggregate, these studies provide the preclinical framework for an ongoing clinical trial testing this small-molecule inhibitor to improve patient outcome in MM. Preclinical activity of P276-00 in myeloma N Raje et al
